Bionime Corp (4737) - Total Liabilities
Based on the latest financial reports, Bionime Corp (4737) has total liabilities worth NT$3.44 Billion TWD (≈ $108.44 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 4737 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Bionime Corp - Total Liabilities Trend (2009–2025)
This chart illustrates how Bionime Corp's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Bionime Corp assets under control.
Bionime Corp Competitors by Total Liabilities
The table below lists competitors of Bionime Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ceres Global Ag Corp
TO:CRP
|
Canada | CA$142.01 Million |
|
Duksan Hi Metal Co.Ltd
KQ:077360
|
Korea | ₩320.20 Billion |
|
MCH Group AG
SW:MCHN
|
Switzerland | CHF254.89 Million |
|
Ugro Capital Limited
NSE:UGROCAP
|
India | Rs111.69 Billion |
|
Gala Precision Engineering
NSE:GALAPREC
|
India | Rs819.80 Million |
|
Kiler Gayrimenkul Yatirim Ortakligi AS
IS:KLGYO
|
Turkey | TL7.91 Billion |
|
Coast Entertainment Holdings Ltd
AU:CEH
|
Australia | AU$40.16 Million |
|
Aroa Biosurgery Ltd
AU:ARX
|
Australia | AU$14.34 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Bionime Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of Bionime Corp to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.85 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bionime Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bionime Corp (2009–2025)
The table below shows the annual total liabilities of Bionime Corp from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$3.95 Billion ≈ $124.41 Million |
+1.45% |
| 2024-12-31 | NT$3.89 Billion ≈ $122.63 Million |
+17.68% |
| 2023-12-31 | NT$3.31 Billion ≈ $104.20 Million |
+13.95% |
| 2022-12-31 | NT$2.90 Billion ≈ $91.45 Million |
+16.67% |
| 2021-12-31 | NT$2.49 Billion ≈ $78.38 Million |
+3.05% |
| 2020-12-31 | NT$2.41 Billion ≈ $76.06 Million |
+2.41% |
| 2019-12-31 | NT$2.36 Billion ≈ $74.27 Million |
-9.20% |
| 2018-12-31 | NT$2.60 Billion ≈ $81.80 Million |
+13.01% |
| 2017-12-31 | NT$2.30 Billion ≈ $72.38 Million |
+11.54% |
| 2016-12-31 | NT$2.06 Billion ≈ $64.89 Million |
+1.70% |
| 2015-12-31 | NT$2.03 Billion ≈ $63.81 Million |
-38.99% |
| 2014-12-31 | NT$3.32 Billion ≈ $104.60 Million |
-3.87% |
| 2013-12-31 | NT$3.45 Billion ≈ $108.81 Million |
+31.25% |
| 2012-12-31 | NT$2.63 Billion ≈ $82.90 Million |
+49.00% |
| 2011-12-31 | NT$1.77 Billion ≈ $55.64 Million |
+552.49% |
| 2010-12-31 | NT$270.64 Million ≈ $8.53 Million |
+7.74% |
| 2009-12-31 | NT$251.19 Million ≈ $7.91 Million |
-- |
About Bionime Corp
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTE… Read more